Zeitschrift für Gastroenterologie, Table of Contents Z Gastroenterol 2018; 56(11): 1423-1429DOI: 10.1055/a-0756-5491 Mitteilungen der DGVS © Georg Thieme Verlag KG Stuttgart · New YorkStellungnahme zur frühen Nutzenbewertung nach § 35a SGB V von Darvadstrocel Recommend Article Abstract Buy Article(opens in new window) Full Text References Literatur 1 Gecse KB, Bemelman W, Kamm MA. et al. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn’s disease. Gut 2014; 63: 1381-1392 2 Panes J, Garcia-Olmo D, Van Assche G. et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn’s disease: a phase 3 randomised, double-blind controlled trial. Lancet 2016; 388: 1281-1290 3 Panes J, Garcia-Olmo D, Van Assche G. et al. Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn’s Disease. Gastroenterology 2018; 154: 1334-1342 e4 4 Van Assche G, Vanbeckevoort D, Bielen D. et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn’s disease. Am J Gastroenterol 2003; 98: 332-339
